- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02445482
SOLTI Breast Cancer Molecular Screening Program (AGATA) (AGATA)
SOLTI Molecular Screening Program: a Pilot Study to Implement Personalized Therapy for Patients With Advanced or Metastatic Breast Cancer
In recent years, the advance in high-throughput techniques, such as microarrays and next gen sequencing (NGS) technologies, have allowed a more precise classification of the breast cancer molecular subtypes and a more personalized approach to anti-cancer therapy. To date, conventional methods to select patients for clinical trials with anti-targeted agents according to molecular criteria are generally limited to the analysis of a few biomarkers. Recent studies have shown how this strategy is inappropriate in case of infrequent molecular alterations and that the ideal strategy would consist in simultaneous examination of large numbers of actionable genomic alterations.
This is the first genomic screening platform ever attempted in Spain. By this molecular platform SOLTI aims to increase the likelihood of a patient being included in a trial designed specifically for her molecular tumor type. Thus, the primary objective of this pilot study is to determine the Platform's effectiveness to include patients in clinical trials with targeted agents based on the tumor molecular profiling.
Study Overview
Detailed Description
This is a prospective, multicenter, pilot study conducted in eight sites located in Spain. Up to 260 female or male patients, between 18-70 years with advanced or metastatic breast cancer will be screened. These patients will be about to receive, or receiving, or will have received treatment for their disease in either a clinical trial or the healthcare setting. Quality of life score according to ECOG scale ≤ 2 and a minimal life expectancy of 3 months. Upon signed inform consent and confirmation of eligibility criteria, tumor samples will be obtained from the patients either by biopsy of metastatic cancer or from archived tissue previously available at the site, and their genomic profile will be analyzed. It will be assessed the mutational status of a panel of genes considered relevant to the tumor biology and treatment. Detected variants /mutations in samples will not be classified according to their origin somatic or germline, since no normal paired DNA will be analyzed. Should any clinical trial match the patient's molecular profile, she/he will be offered to participate in it and the available samples left after sequencing will be supplied when a central confirmation would be requested. The patient's clinical data will be collected on a quarterly basis until death or consent withdrawal.
Mutation testing will be carried out at three laboratories experienced in high-throughput sequencing techniques: the VHIO Cancer Genomics Core laboratory of Barcelona, at Genomics Laboratory of the Research Institute of the Doce de Octubre University Hospital of Madrid and at the Genomics laboratory of the University Clinical Hospital of Valencia. There is a need to join efforts, set standards and optimize procedures for the benefit of all patients, so that the opportunity to participate in a genomic screening program can be offered to the great majority of hospitals that lack the technology required for these tests.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain
- Hospital Clinic de Barcelona
-
Barcelona, Spain
- Hospital Universitari Vall d' Hebron
-
Girona, Spain
- Institut Català d' Oncologia de Girona
-
Madrid, Spain
- Hospital Universitario 12 De Octubre
-
Madrid, Spain
- Complejo Integral Oncologico Clara Campal
-
Sevilla, Spain
- Hospital Universitario Virgen del Rocío
-
Valencia, Spain
- Hoapital Universitario Arnau de Vilanova
-
Valencia, Spain
- Hospital Universitario Clinic de Valencia
-
-
Barcelona
-
Hospitalet de Llobregat, Barcelona, Spain
- Institut Català d' Oncologia
-
-
Islas Baleares
-
Palma de Mallorca, Islas Baleares, Spain
- Hospital Universitario Son Espases
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Female or Male patients
- Between 18 and 70 years of age
- Signed informed consent prior to any screening procedure
- Advanced or Metastatic breast cancer of any subtype confirmed both pathologically and radiologically (stage IIIb- IV disease)
- The patient may present with a responding, stable or progressive disease
- The subjects must be about to receive, or receiving, or will have completed treatment for their metastatic disease with any line of treatment in either a clinical trial or the healthcare setting
- Availability of one archived initial or metastatic tumor sample. If archived material were not available, a biopsy of the metastatic cancer should be performed to obtain such material.
- Measurable or non-measurable disease
- Quality of life score according to ECOG scale ≤ 2
- Minimal life expectancy of 3 months
Exclusion Criteria:
- Presence of progressive disease at the time of inclusion requiring treatment initiation before genomic profile results are obtained
- LVEF<50% (MUGA)
- Inadequate bone marrow reserve or organ dysfunction shown by any of the following laboratory values:
- Absolute neutrophil count
- Platelet count< 100 x 109/L
- Hemoglobin < 90 g/dL
- AST/ALT > 2.5 times the upper limit of normality if no demonstrable hepatic metastases, or > 5 times the upper limit of normality in the presence of hepatic metastases
- Total bilirubin > 1.5 times the upper limit of normality
- Creatinine>1.5 times the upper limit of normal
- Corrected calcium > upper limit of normality
- Phosphate > upper limit of normality
- Presence of any other type of cancer, except suitably
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Platform's effectiveness mesured as the proportion of patients included in clinical trials with targeted agents based on the tumor molecular profiling
Time Frame: 30 months
|
30 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Characterization of the genomic profiles of the breast cancer patients included in the program listing the percentage of mutations deemed potentially actionable
Time Frame: 30 months
|
30 months
|
List of the potential barriers of the program
Time Frame: 30 months
|
30 months
|
Comparison of the percentage of patients included in clinical trials according to their genomic profile between the different panels and sequencing methods.
Time Frame: 30 months
|
30 months
|
Percentage of the patients alive and without progression (PFS) and percentage of patients alive (OS) of the patients receiving any targeted therapy based on molecular profiling
Time Frame: 30 months
|
30 months
|
Comparison of the PFS and OS percentages of patients included in clinical trials according to the genomic profile of their tumor with those of patients not assigned to these clinical trials
Time Frame: 30 motnhs
|
30 motnhs
|
Collaborators and Investigators
Investigators
- Principal Investigator: Eva Ciruelos, MD, SOLTI Breast Cancer Research Group
- Principal Investigator: Sonia Pernas, MD, SOLTI Breast Cancer Research Group
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SOLTI-1301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Breast Cancer
-
Gilead SciencesRecruitingStudy of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (ASCENT-J02)Advanced Solid Tumor | Metastatic Urothelial Cancer | Metastatic Triple-Negative Breast Cancer | HR+/HER2- Metastatic Breast CancerJapan
-
BriaCell Therapeutics CorporationRecruitingBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer Metastatic | End Stage CancerUnited States
-
GlycoMimetics IncorporatedTerminatedBreast Cancer | Breast Cancer Metastatic | HR+ Metastatic Breast CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyCompletedMetastatic Breast Cancer | Metastatic Triple Negative Breast CancerJapan, Belgium, France, Netherlands
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | Postmenopausal Women | Locally Advanced Metastatic Breast CancerIsrael
-
BriaCell Therapeutics CorporationLumaBridgeEnrolling by invitationBreast Cancer | Breast Neoplasm | Metastatic Breast Cancer | Breast Cancer MetastaticUnited States
-
Prof. Wolfgang JanniEli Lilly and CompanyRecruitingHormone Receptor-positive Metastatic Breast Cancer | HER2-negative Metastatic Breast CancerGermany, Switzerland
-
Hoffmann-La RocheCompletedHER2-Positive Metastatic Breast Cancer | HER2-Negative Metastatic Breast Cancer | Locally Advanced or Early Breast CancerUnited States
Clinical Trials on Biopsy
-
UNICANCERNational Cancer Institute, FranceActive, not recruitingTriple-Negative Breast NeoplasmFrance
-
Postgraduate Institute of Medical Education and...CompletedLung Cancer | Endobronchial GrowthIndia
-
Chandan SenTerminatedWound Leg | Non-Diabetic Patients | Chronic Ulcer Leg/FootUnited States
-
Duke UniversityCompletedInterstitial Lung DiseaseUnited States
-
Centre Hospitalier Universitaire de NiceUnknownParodontitis Aggressive | Parodontitis ChronicFrance
-
Ardeshir RastinehadPhilips HealthcareRecruitingProstate Cancer | Prostate Disease | Elevated Prostate Specific Antigen | Family History of Prostate Cancer | Positive Digital Rectal ExamUnited States
-
Odense University HospitalNot yet recruitingProstate Cancer (Diagnosis)
-
Shandong Cancer Hospital and InstituteUnknownBreast Cancer | Sentinel Lymph NodeChina
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer
-
Mayo ClinicErbe USA IncorporatedCompletedLung Diseases, Obstructive | Bronchi--Diseases | Lesions MassUnited States